FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and TherapyLucie C. Kompier, Ellen C. Zwarthoff, Irene Lurkin et al.|PLoS ONE|2010Cited by 314
Prediction of Progression of Non–Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective StudyMaximilian Burger, Ellen C. Zwarthoff, Madelon N.M. van der Aa et al.|European Urology|2008Cited by 178
A Simple and Fast Method for the Simultaneous Detection of Nine Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer and Voided UrineJohanna M.M. van Oers, Ellen C. Zwarthoff, Irene Lurkin et al.|Clinical Cancer Research|2005Cited by 162
Cystoscopy Revisited as the Gold Standard for Detecting Bladder Cancer Recurrence: Diagnostic Review Bias in the Randomized, Prospective CEFUB TrialMadelon N.M. van der Aa, Theodorus van der Kwast, Ellen C. Zwarthoff et al.|The Journal of Urology|2009Cited by 126
Patients’ perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparisonMadelon N.M. van der Aa, Marie‐Louise Essink‐Bot, Ewout W. Steyerberg et al.|British Journal of Urology|2007Cited by 111